ICM
XRAY icon

Invenomic Capital Management’s Dentsply Sirona XRAY Stock Holding History

Invenomic Capital Management’s Portfolio XRAY Stock Details XRAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$52.1M Buy
4,909,808
+519,715
+12% +$5.67M 3.11% 4
2026
Q1 		$50.9M Sell
4,390,093
-741,943
-14% -$9.25M 2.34% 6
2025
Q4 		$58.7M Buy
5,132,036
+780,837
+18% +$9.17M 2.73% 3
2025
Q3 		$55.2M Buy
4,351,199
+1,425,637
+49% +$20.7M 2.67% 3
2025
Q2 		$46.5M Buy
2,925,562
+448,656
+18% +$6.71M 2.64% 2
2025
Q1 		$37M Sell
2,476,906
-162,255
-6% -$2.87M 1.87% 10
2024
Q4 		$50.1M Buy
2,639,161
+1,762,428
+201% +$37.3M 2.38% 4
2024
Q3 		$23.7M Buy
+876,733
New +$22.4M 1.3% 25

Other funds holding XRAY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Lazard Asset Management
Lazard Asset Management New York $66.1B AUM 33.53% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
SCA
Southpoint Capital Advisors New York $4.4B AUM 49.36% 1-Year Est. Return
CB
Cooke & Bieler Philadelphia, Pennsylvania $8.65B AUM 9.66% 1-Year Est. Return

Invenomic Capital Management's XRAY Position: Q2 2026 in Review

Invenomic Capital Management increased its Dentsply Sirona (XRAY) stake by 12% in Q2 2026, buying an estimated $5.67M and bringing the position to 4,909,808 shares worth $52.1M. The position accounts for 3.11% of the portfolio, ranked #4.

Invenomic Capital Management first reported a position in XRAY in Q3 2024 and has held it in 8 quarters since. The position peaked at $58.7M in Q4 2025. 373 funds tracked by Wall St. Rank hold XRAY as of Q2 2026.

  • Invenomic Capital Management held 4,909,808 shares of Dentsply Sirona worth $52.1M as of Q2 2026.
  • Invenomic Capital Management bought 519,715 Dentsply Sirona shares in Q2 2026, an estimated $5.67M.
  • Dentsply Sirona made up 3.11% of Invenomic Capital Management's portfolio in Q2 2026, its #4 holding.
  • Invenomic Capital Management first reported a position in Dentsply Sirona in Q3 2024 and has held it in 8 quarters since.
  • Invenomic Capital Management's Dentsply Sirona position peaked at $58.7M in Q4 2025.
  • 373 funds tracked by Wall St. Rank held Dentsply Sirona as of Q2 2026.

Based on Invenomic Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.